ATE222263T1 - Prostata-spezifische antigen inhibitore - Google Patents

Prostata-spezifische antigen inhibitore

Info

Publication number
ATE222263T1
ATE222263T1 AT98118104T AT98118104T ATE222263T1 AT E222263 T1 ATE222263 T1 AT E222263T1 AT 98118104 T AT98118104 T AT 98118104T AT 98118104 T AT98118104 T AT 98118104T AT E222263 T1 ATE222263 T1 AT E222263T1
Authority
AT
Austria
Prior art keywords
prostate
specific antigen
lys
inhibitors
antigen inhibitors
Prior art date
Application number
AT98118104T
Other languages
English (en)
Inventor
Kozue Shibata
Jun-Ichi Kajihara
Kazuyuki Hirano
Original Assignee
Japan Chem Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Chem Res filed Critical Japan Chem Res
Application granted granted Critical
Publication of ATE222263T1 publication Critical patent/ATE222263T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98118104T 1997-09-24 1998-09-24 Prostata-spezifische antigen inhibitore ATE222263T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP27819097A JP3904689B2 (ja) 1997-09-24 1997-09-24 前立腺特異抗原の阻害剤

Publications (1)

Publication Number Publication Date
ATE222263T1 true ATE222263T1 (de) 2002-08-15

Family

ID=17593854

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98118104T ATE222263T1 (de) 1997-09-24 1998-09-24 Prostata-spezifische antigen inhibitore

Country Status (5)

Country Link
US (1) US6284734B1 (de)
EP (1) EP0905142B1 (de)
JP (1) JP3904689B2 (de)
AT (1) ATE222263T1 (de)
DE (1) DE69807166T2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448086B1 (en) 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer
FI116467B (fi) * 2000-09-29 2005-11-30 Licentia Oy Uudet peptidiligandit

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569742A (en) * 1994-06-22 1996-10-29 The Salk Institute For Biological Studies Centrally truncated NPY cyclic peptides
US5854206A (en) * 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer

Also Published As

Publication number Publication date
EP0905142B1 (de) 2002-08-14
JP3904689B2 (ja) 2007-04-11
DE69807166D1 (de) 2002-09-19
JPH1192397A (ja) 1999-04-06
EP0905142A1 (de) 1999-03-31
DE69807166T2 (de) 2002-12-12
US6284734B1 (en) 2001-09-04

Similar Documents

Publication Publication Date Title
NO993396D0 (no) Kinolin- ig kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
BR9707819A (pt) Imunogenos peptidicos
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
DE60331049D1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
CY1107637T1 (el) Θεραπευτικη αγωγη καρκινου προστατη με αντισωματα αντι - erbb2
ATE264863T1 (de) 28-epirapaloge
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
BR9805544A (pt) Uso de um composto.
IS6375A (is) Lyfjagjöf til öftrunar á blöðruhálskrabbameini
DE59807921D1 (de) Hochleistungs-Druckwellenquelle
NO20015516L (no) Preparater og anvendelser av ET743 for behandling av kreft
DK0925069T3 (da) Anvendelse af Cetrorelix til behandling af godartet prostatahypertrofi og prostatacancer
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
EP1320376A4 (de) Behandlung von prostatakrebs
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
SE9904377D0 (sv) Pharmaceutical combinations
DE69814894D1 (de) Isochinolin derivate als urokinase inhibitoren
DK0972024T4 (da) Tumorsuppressor designeret TS10Q23.3
PT984777E (pt) Piperazinas arilsubstituidas uteis no tratamento da hiperplasia benigna da prostata
IS5366A (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
IT1303677B1 (it) Dispositivo per il trattamento termico di pezzi.
EP1018551A4 (de) Megsin-protein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties